FDA Approves Generic Release of Abilify

The U.S. Food and Drug Administration (FDA) approved the first AB-rated generics to Bristol-Myers Squibb and Otsuka’s Abilify® (aripiprazole) tablets, an atypical antipsychotic drug commonly used for treating schizophrenia and bipolar disorder. The agency approved generics from Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals and Torrent Pharmaceuticals. At least one manufacturer, Teva, announced the launch of [...] Continue reading →

The DEA Finally Decides To Reschedule Hydrocodone

Hydrocodone Rescheduled Last week the DEA released a final rule on the rescheduling of hydrocodone removing it from the schedule III controlled substances list in favor of a schedule II designation. To be clear, this decision specifically addresses hydrocodone combination products (i.e., hydrocodone-acetaminophen formulations such as Vicodin) as hydrocodone by itself has always been a schedule II [...] Continue reading →

New Additions to Tower Executive Team

In our continued commitment  to build a unique MSP compliance model focused on  identification, intervention and involvement to stage claims prior to MSA and settlement, I am pleased to announce the addition of two key individuals to the Tower MSA Partners executive team. Scott E. Yasko, MBA Scott joined tower in July to serve as EVP, [...] Continue reading →

Dangers of Tramadol Recognized

On the Job Recently, the DEA made the decision to reclassify Tramadol as a schedule IV controlled substance and the decision will officially go into effect on August 18th. Tramadol is an opioid analgesic and aside from its generic form it can also be found in brand names such as Ultram, ConZip and Ryzolt. This is considerably important news for [...] Continue reading →

Chronic Pain Can Be Managed With Alternative Therapies

alternative therapy Traumatic injuries and opioid therapy can alter the pain pathways in the central nervous system, and this process is called neuroremodeling. This can cause unwanted or undesirable reactions to pain and negatively impact the recovery process. There are several approaches to reversing the neuroremodeling, some of these alternative treatments include cognitive behavior therapy and opioid [...] Continue reading →

Can A Medicare Beneficiary Obtain Coverage Under ACA Compliant Major Medical Plan?

Medicare Beneficiary This was a question raised recently within the NAMSAP (National Association of MSA Professionals) listserv.   While it seemed simple and straightforward, it generated so much interest from so many within our organization, I thought it worthy of a blog post to communicate both dialogue and  dilemma . Setting the Stage n 2011, a medical liability claim was filed [...] Continue reading →
Page 1 of 7123456»...Last »